fcr

Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.

Rozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pathogenic IgG in autoimmune and alloimmune diseases.

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.

Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

Ofatumumab is a humanized monoclonal antibody targeting CD20. Ofatumumab acts on CD20-expressing B lymphocytes, inducing antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is an IgG1 antibody inhibitor derived from mice, specifically targeting rat FcRn heavy chain heterodimers.

Anti-RatFcRnheavy chain heterodimers Antibody (1G3) is a mouse-derived antibody, specifically targeting the FcRn heavy chain heterodimers. The isotype control for Anti-RatFcRnheavy chain heterodimers Antibody (1G3) is designated as MouseIgG1kappa, Isotype Control.

Anti-FcRH5 Antibody (MFRF3266A, DFRF4539A Naked Antibody) is a highly specific monoclonal antibody targeting FcRH5 (also known as IRTA2 or CD307e) and serves as the antibody backbone for the ADC DFRF4539A (RG-7598), which is used in research related to relapsed or refractory multiple myeloma.

hIgG–hFc receptor-IN-1 is a compound that inhibits the protein-protein interaction between human immunoglobulin G and the human neonatal Fc receptor (hIgG-hFcRn), with an IC50 of 2 μM.

(±)-Haloxyfop (Haloxyfop Acid) is a herbicide.

Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the study of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized bispecific antibody targeting FcRH5/CD3. It binds to FcRH5 expressed on multiple myeloma (MM) cells and CD3 on T cells, promoting T cell synapse formation and inhibiting B-cell malignancies.

F-CRI1, a potent STING agonist with a dissociation constant (K d) of 40.62 nM, is an 18F-labeled radioactive probe employed for visualizing STING in the tumor microenvironment [1].

Talizumab (TNX 901) is a humanized IgG1 monoclonal antibody that specifically targets circulating immunoglobulin E (IgE). it binds to free IgE not already bound by the high-affinity IgE receptors (FcεRI) present on mast cells and basophils, which leads to the marked downregulation of these receptors and additionally inhibits allergen-specific T-cell activation by interfering with antigen processing and presentation activities.

Transferrin aldifitox (TF-CRM107), a conjugate of diphtheria toxin CRM107 with transferrin, can be used for anticancer research [1].

Eclazolast (RHC 2871) is a lipophilic anti-allergic compound that inhibits mediator release in a mast cell model.Eclazolast inhibits extracellular secretion by affecting only the direct processes associated with Fc(epsilon)RI in the cell.The effect of Eclazolast is highly dependent on the concentration of antigen that triggers the cell.

Poseltinib is an orally active, selective, and irreversible inhibitor of Bruton's tyrosine kinase (BTK), with an IC50 value of 1.95 nM. Poseltinib demonstrates 0.3-, 2.3-, and 2.4-fold higher selectivity for BTK over BMX, TEC, and TXK, respectively. Poseltinib covalently binds to cysteine 481 in BTK’s active site, thereby inhibiting BCR-, FcR-, and TLR-mediated signaling pathways.

CDX-1140 is a human IgG2 CD40 agonist antibody. It activates dendritic (DC) and B cells and induces NF-kB stimulation in CD40-expressing reporter cell lines. CDX-1140 functions independently of Fc receptor binding and works synergistically with natural CD40L signaling. It exhibits both direct and immune-mediated antitumor activity, making it useful for lymphoma and solid tumor research.

2-Acetoxy-3-deacetoxycaesaldekarin E shows significant dose-dependent inhibitory effects on Plasmodium falciparum FCR-3/A2 growth in vitro.

Caesalmin B shows significant dose-dependent inhibitory effects on Plasmodium falciparum FCR-3/A2 growth in vitro.

Norcaesalpinin E shows antimalarial activity against the malaria parasite Plasmodium falciparum FCR-3/A2 clone in vitro, with an IC50 value of 0.090 microM.